Doctor of Osteopathy Program year 2023 Source: CMS Open Payments, 2026 publication

Peter Barry

Sports Medicine Clark, NJ Doctor of Osteopathy

NPI 1609844828 CMS profile 299179

67 Walnut Ave Ste 202, Clark, NJ 07066

Open in the dashboard

General payments

$17

1 record reported · program year 2023

Research payments

$0

Paid to them · None reported · program year 2023

Ownership & investment interest

$0

None reported

Through program year 2023, Peter Barry of Clark, NJ is reported in the CMS Open Payments database as having received $17 across 1 general payment and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 2nd percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2023 General $17 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Peter Barry
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Peter Barry were reported at $0. Among 132 Sports Medicine profiles paid that year, the median was $99 and the middle half received between $33 and $256.

Show as a table
Year Peter Barry Sports Medicine median Middle half National median
2019 $0 $131 $46–$324 $163
2020 $0 $96 $34–$276 $114
2021 $0 $120 $33–$421 $132
2022 $0 $107 $31–$274 $149
2023 $17 $63 $25–$180 $160
2024 $0 $104 $28–$282 $164
2025 $0 $99 $33–$256 $169

Breakdown

Who paid General payments · program year 2023
  1. Xeris Pharmaceuticals, Inc. $17 1 payment

Every payment, record by record

What the payments were for General payments · program year 2023
  1. Food and Beverage $17 1 payment
Products named General payments · program year 2023
  1. GVOKE HYPOPEN $17 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 122 drugs

Part D claims

5,526

Median for Internal Medicine: 777

Drug cost

$479,542

Median for Internal Medicine: $73,373

Branded share of claims

22.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 89 $94,988
Jardiance Empagliflozin Brand 47 $61,911
Eliquis Apixaban Brand 41 $50,106
Rybelsus Semaglutide Brand 19 $41,032
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 29 $27,999
Xarelto Rivaroxaban Brand 28 $24,452
Myrbetriq Mirabegron Brand 22 $23,956
Bydureon Bcise Exenatide Microspheres Brand 20 $19,338
Mounjaro Tirzepatide Brand 19 $19,296
Farxiga Dapagliflozin Propanediol Brand 11 $16,744

The 10 drugs with the highest cost, of 122 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 105 billing codes

Paid by Medicare

$161,790

Of which drugs: $22,871

Medicare patients

340

Average age 73

Services billed

3,751

173 women, 167 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 41%
Diabetes 29%
Ischemic heart disease 29%
Heart failure 18%
Cancer 16%
Chronic kidney disease 15%
Atrial fibrillation 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 43 43 $12,559
Vaccine for influenza for injection into muscle 90662 Office 65 65 $5,157
Pneumococcal conjugate vaccine, 15 valent (pcv15), for intramuscular use 90671 Office 12 12 $2,982
Injection, methylprednisolone acetate, 1 mg J1010 Office 12 1,041 $100
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 11 30 $28

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

1 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record